具有 CD38(-)CD73(-)Tim-3(-)HLA-DR(+) 表型的 CAR-T 细胞预测 tisagenlecleucel 治疗 B 细胞前体 ALL 的疗效
CAR-T cells with the CD38(-)CD73(-)Tim-3(-)HLA-DR(+) phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.
FRONTIER PAPERS
CAR-T cells with the CD38(-)CD73(-)Tim-3(-)HLA-DR(+) phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
我们的数据表明,基于 CAR.CD123-NK 细胞的创新型即用型治疗策略具有可行性,其特点是疗效显著,且与 CAR.CD123-T 细胞相比安全性更好。这些发现不仅为难治/耐药 AML 患者的治疗开辟了一个新的有趣前景,也为进一步研究 CAR-NK 细胞在那些以传统 T 效应细胞极难靶向为特征的其他癌症中的应用开辟了前景。
Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia.
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia.
SOHO State of the Art Updates and Next Questions: Novel Therapies in T-ALL: From CAR-T to Novel Targets.
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
Juvenile myelomonocytic leukemia stem cells are sensitive to NK cell-mediated lysis and express targetable antigens.
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。